The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
Abstract
BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“weight gain was also significantly higher in the treatment group [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“a randomized controlled trial including 101 patients with either pre‐ or type 2 diabetes found that 51% in the Pioglitazone group (45 mg/day) had resolution of NASH and 58% achieved the primary outcome of the study (reduction of ≥2 NAS points in two histologic categories without worsening of fibrosis), both significantly [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“Pioglitazone treatment was also associated with a significant improvement in fibrosis score.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Research works printed but not linked: 1
- Bril F, 2015, Diabetes, 64, A337
Cited by
Items 901–1,000 of 1,001
Kaji, K., & Yoshiji, H. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.57
Stepanov, Y. М. (2019) · GASTROENTEROLOGY · doi:10.22141/2308-2097.53.2.2019.168984
Obesity in the Pathophysiology of Diabetes
Paniagua, J. A., & Vidal‐Puig, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_13
Chang, C., & Sakaguchi, M. (2019) · Diabetology International · doi:10.1007/s13340-019-00405-w · Cited by 1
Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis
Miyake, T., & Hiasa, Y. (2019) · Springer eBooks · doi:10.1007/978-981-13-7979-6_1
Gómez, E. V., & Chalasani, N. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15488
Die verfettete Leber in der Hausarztpraxis: Seminar / Nicht-alkoholische Fettlebererkrankung
Schulte‐Frohlinde, E. (2020) · MMW - Fortschritte der Medizin
Nichtalkoholische Fettlebererkrankung und Typ‑2‑Diabetes: Management und Therapie
Pützer, J., & KAHL, S. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00649-0
NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications
Scorletti, E., & Byrne, C. D. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_9
Puri, P. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.002
Ruolo dei farmaci antidiabete nel trattamento della NAFLD
Mantovani, A. (2021) · il Diabete · doi:10.30682/ildia2102b
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease
Brodosi, L., Marchignoli, F., Marchesini, G., & Petroni, M. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1980538
Morgan, J., Howick, S., & Belton, V. (2010)
Management of type 2 diabetes without insulin: An update for the PCP
Thiruvengadam, S., & Peter, P. R. (2021) · Disease-a-Month · doi:10.1016/j.disamonth.2021.101290 · Cited by 1
Tsai, L.-W., Lu, Y.-H., Dubey, R., & Chiou, J. (2021) · Journal of Diabetes Research · doi:10.1155/2021/7692447
Viral alcoholic and fatty liver diseases
Zigmond, E., & Shouval, D. (2021) · doi:10.1093/med/9780198816805.003.0074
A nem alkoholos zsírmájbetegség
Baffy, G. (2022) · Lege Artis Medicinae · doi:10.33616/lam.32.003
Phospholipids in non-alcoholic fatty liver disease
Skvortsov, V. V., Lunkov, M. V., Tinaeva, R. S., & Skvortsova, E. M. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-6-92-99
Targher, G., Mantovani, A., & Bonora, E. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_17-2
Gautam, C., Sharma, J., Singla, M., Tiwana, I. K., & Singh, H. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.1.1.33
II. Nonalcoholic Fatty Liver Disease NAFLD as an Harbinger of Cancer: Implications for India
(2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.003
Targher, G., Mantovani, A., & Bonora, E. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_17
Strategies for the Management of Type 2 Diabetes
Winocour, P. H., & Zac‐Varghese, S. (2022) · doi:10.1093/med/9780198870197.003.0259
Nonalcoholic Steatohepatitis-Induced Hepatocellular Carcinoma
Hakami, A., & Elmakki, E. E. (2022) · King Khalid University Journal of Health Sciences · doi:10.4103/kkujhs.kkujhs_1_22
Raizada, N., & Madhu, S. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01130-y
Therapeutic Approach to NAFLD-NASH
Sfikas, G., & Valsamidis, I. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107487
Nonalcoholic fatty liver disease
van Son, K. C., Holleboom, A. G., & Tushuizen, M. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822186-0.00024-9 · Cited by 2
Metabolic-associated fatty liver disease: pharmacological management
Shi, Y., & Fan, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00010-0
Corsi, M. L. S., de Blasio, H. M., Nascimento, R. F. V., Baltazar, J., do Carmo, A. P. P., & Chehter, E. Z. (2023) · Seven Editora eBooks · doi:10.56238/medfocoexplconheci-028
Tkach, S. M. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-3-62 · Cited by 1
Jiang, W., Yan, Y., Yuan, G., & Du, T. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.12.010
Sanyal, A. J., Muthiah, M. D., & Tan, E. X. X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00029-3
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Self-citationBurroughs‐Ray, D., Whitwell, S. A., Williams, N., Imran, H., & Jackson, C. (2024) · Southern Medical Journal · doi:10.14423/smj.0000000000001669
Ress, C. (2024) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-024-00191-6
Collaboration of alogliptin and pioglitazone: a double hit on the target
Салухов, В. В., Анатольевна, К. Е., & Ilyinskaya, Т. A. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-157
Barb, D., Kalavalapalli, S., Leiva, E. G., Bril, F., Huot-Marchand, P., Lucile, L., Rosenberg, J. T., Junien, J., Broqua, P., Rocha, A. O., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4840179
Self-citationFocus on Non-Alcoholic Fatty Liver Disease
Voronina, L. P. (2024) · Рецепт · doi:10.34883/pi.2024.27.2.004
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Lean NAFLD: Prevalence, risk factors/pathogenesis, natural history, and treatment
Ito, T., & Takahashi, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00001-7
Choudhuri, G., Kalel, S. R., Sharma, Z. D., & Bansal, R. (2024) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2024.15.00585 · Cited by 3
Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis
Abdel-Samiee, M., Ibrahim, E. S., Kohla, M., Abdelsameea, E., & Salama, M. (2024) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v15.i6.97381
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.69 · Cited by 1
Self-citationHussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Zabotina, E. E., Хабарова, Ю. А., & Стукова, Н. Ю. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-229-9-96-109
覃, 胜. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153651
Hallazgos por imagen de las enfermedades hepáticas por depósito
Rouilleault, A. C. I., Jiménez, S. M., Moreno, J., Belmonte, E., Ayuso, J. R., & García‐Criado, Á. (2025) · Radiología · doi:10.1016/j.rx.2025.02.005
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
Razzak, I. A., Razzak, I. A., Noureddin, M., & Trivedi, H. D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002210 · Cited by 1
Kakita, N., Jono, M., Tsumuro, H., Satake, S., Iwatani, S., Aoi, K., & Katayama, K. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02185-0 · Cited by 1
Rebelos, E., & Kounatidis, D. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00273-9
Type 2 diabetes and fatty liver disease. Part 2: management
Morris, D. (2025) · Independent Nurse · doi:10.12968/indn.2025.8.12
Pinheiro, M. M., Afonso, M. B., & Rodrigues, C. M. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-823524-9.00003-4
Peroxisome proliferator-activated receptors in metabolic and renal health: a comprehensive review
Vahora, N., Yathindra, M. R., James, D. M., Sharma, R., Panvalkar, A. S., Shyam, G., & Swathi, N. L. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20252817
Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
Zeb, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00023-8 · Cited by 1
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Metabolic dysfunction-associated steatotic liver disease in metabolic syndrome
Drapkina, O. M., & Nedogoda, S. V. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6541 · Cited by 3
Xie, C., Liu, T., Zhong, Y., Li, Z., Xu, J., Zhao, Z., Wang, X., & Gao, P. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303396313250904204350 · Cited by 1
Saviano, A., & Serfaty, L. (2025) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)46793-x
Pharmakotherapie des PCOS aus internistischer Sicht
Lee-Barkey, Y. H., Stratmann, B., Klose, J. M., & Tan, S. (2025) · Die Gynäkologie · doi:10.1007/s00129-025-05426-y
Huang, S., Xi, Y., Hong, Y., & Hu, C. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2720-5290
Demidova, T. Y., Titova, V. V., Levitskaya, A. N., & Gyozalyan, M. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-456
Exploring the therapeutic potential of deuterated PPARγ agonists for NASH
Pang, X., Cui, D., Liu, R., Lv, B., & Wang, C. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130489
Park, J., Kim, G., Kim, B., Han, K.-D., Kwon, S. Y., Park, S. H., Lee, Y.-B., Jin, S.-M., & Kim, J. H. (2022) · Figshare · doi:10.6084/m9.figshare.19608174
Chung, G. E., Jeong, S.-M., Cho, E. J., Yoon, J. W., Yoo, J.-J., Cho, Y., Lee, K.-N., Shin, D. W., Kim, Y. J., Yoon, J.-H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26550982
Yan, H., Wu, W., Chang, X., Xia, M., Ma, S., Wang, L., & Gao, J. (2021) · Figshare · doi:10.6084/m9.figshare.13521100
A Comprehensive Systematic Review on Therapeutic Discovery of NAFLD Drugs
Vathsalya, S. K., Gnanavel, A., Bindu, N. H., Kumar, S. S., & Kumar, B. N. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00655
Kalra, S. S. S., Sadasivam, B., Najmi, A., & Chaurasia, J. K. (2025) · Cureus · doi:10.7759/cureus.99891
Mihalache, L., & Graur, L. I. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_8
De Novo and Recurrent Metabolic Dysfunction Associated Steatotic Liver Disease
Parsa, L., & Satapathy, S. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-2624-6_37
Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights
Ghosh, S., Ghosh, A. J., Adhikari, M. D., Tiwary, B. K., & Saha, T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01861-3
Kouti, T., Christodoulou, P., Christodoulides, S., Protopapa, F., Michaeloudes, C., & Farazi, P. A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1767917 · Cited by 1
“Other drugs that have been used for the management of MASH include PPAR agonists, such as pioglitazone, a PPAR γ agonist, which improve histological features of steatohepatitis (68, 69), yet their clinical use is limited by adverse effects and regulatory withdrawal in certain countries (70).”
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502639
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
Diamantopoulos, L. N., Kalligeros, M., Isaacs, S. D., & Mauricio, D. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.001
Halder, S., Hossain, T., Nasrin, N., Reza, R., Samdani, M. N., Shill, M. C., Chowdhury, J. A., & Reza, M. S. (2026) · Nano LIFE · doi:10.1142/s1793984426500030
Abdou, H. A., & Omar, S. A. (2026) · ASIDE Gastroenterology · doi:10.71079/aside.gi.031826446
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease
Kumar, S., Macedo, M. P., Roden, M., & Kashyap, S. R. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.003
Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease
Li, X., Zhang, J., Wei, B., & Tong, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1775516 · Cited by 4
“This finding was further supported by another RCT in biopsy-proven NASH patients, and pioglitazone led to 41% more patients with liver histology alleviation and 32% more patients with NASH resolution, comparing with placebo (Cusi et al., 2016; Adil et al., 2024).”
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63 · Cited by 1
Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
Smati, S. (2019) · theses.fr (ABES) · doi:10.70675/01997f55za990z41e6z96baz8221de2a6281
Rôle de FAT10 dans la sénescence des hépatocytes et le développement de la NASH
Bernard, L. (2023) · theses.fr (ABES) · doi:10.70675/793b0b93z9794z42d4zb8dfz5f3d68268a9b
Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies
Munda, B., Bhutia, C., Deepti, & Khatri, M. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.011
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
“However, adverse effects—including weight gain (typically 2–4 kg), fluid retention, increased fracture risks (particularly in postmenopausal women), and a possible association with bladder cancer—limit broader adoption and necessitate careful patient selection [31].”
Andevari, A. N., Firoozjaee, A. H., Meftah, N., Asciabari, H. A., Bahri, F., Shahandashti, N. E., Fallah, H., & Qujeq, D. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01639-6
Lee, J. W., Oh, E.-J., Cho, S., Kang, J.-H., Gwak, S.-H., Shin, W., Yoon, S., Han, Y., Kim, J., & Kim, K. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179008
Shetty, U. S. A., Batool, A.-E.-Z., Postoev, A., Abdul, R. H. M., Chaudhary, S., Jabeen, S., Wei, C. R., & Amin, A. (2026) · Cureus · doi:10.7759/cureus.109532
“Type 2 diabetes mellitus (T2DM) is highly prevalent among patients with cirrhosis, affecting approximately 20-30% of this population [4,5].”
Uzyanbaev, I. A., Timoshenko, S., Спирина, Л. В., & Матвеева, М. В. (2026) · Current Drug Targets · doi:10.2174/0113894501398066251211070417
Soyaltın, U. E., Aliyeva, N., Balta, C., Celebi, T., & Şimşir, İ. Y. (2026) · Ege Tıp Dergisi · doi:10.19161/etd.1885126
Pfaller, A. T., Veneziano, C., Murthi, S. R., Stöckl, J. B., Shashikadze, B., Flenkenthaler, F., Gorham, J., Moretti, A., Kitanovic, A., Gearing, L. J., et al. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101574 · Cited by 1
Imaging findings of hepatic storage diseases
Rouilleault, A. C. I., Jiménez, S., Moreno, J. A., Belmonte, E., Ayuso, J. R., & García‐Criado, Á. (2026) · Radiología (English Edition) · doi:10.1016/j.rxeng.2026.101670
Nutrition Therapy for Metabolic Liver Disease and Diabetes
Guinane, A., & Pezzuto, D. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch15
Petrakis, V., Rafailidis, P. I., Grapsa, A., Sousanidou, A., Bougiouklou, T., Babaka, N., Panagopoulos, P., & Papazoglou, D. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2897-4761
Saad, M., Rahim, F., Amin, S., Yar, M. A., Batool, A., Nadeem, H., & Khan, S. (2026) · Journal of Gandhara Medical and Dental Science · doi:10.37762/jgmds.13-3.866
Demidov, N. A. D., Demidova, T. Y., & Antsiferov, M. B. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-2-03
Yang, H., Son, S. Y., Song, Y., Choi, H., Do, I., Lee, C. H., & Park, C. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70601
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations
Newsome, J. S. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261466571
“Cusi et al 19 studied the long-term safety and efficacy effects of pioglitazone treatment for NASH in patients with prediabetes or diabetes.”
Lawitz, E., Poordad, F. F., & Goodman, Z. D. (2026) · Liver International · doi:10.1111/liv.70808
Metadata
- Authors
- Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., & Portillo-Sanchez, P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- From University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, and University of Texas Health Science Center at San Antonio and Audie L. Murphy Veterans Affairs Medical Center, San Antonio, Texas.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-09-06
- Volume
- 165
- Issue
- 5
- Pages
- 305-315
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2470709274
- Cited by
- 1,024
- References
- 62
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 109 · 2023: 103 · 2022: 116 · 2021: 131 · 2020: 108 · 2019: 85 · 2018: 85 · 2017: 67 · 2016: 27
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- U.S. Department of Veterans Affairs (1 I01 CX000167-01)
- American Diabetes Association
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, prediabetes, type 2 diabetes, long-term treatment, hypocaloric diet, NASH resolution, liver fibrosis, hepatic triglyceride content, insulin sensitivity, insulin resistance, PPARγ agonists, drug safety, adverse events, liver histopathology, hepatic steatosis
- MeSH terms
- Pioglitazone, Transaminases, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Prediabetic State, Triglycerides, Biomarkers, Weight Gain, Thiazolidinediones, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.